Skip to main content
Explore URMC

menu

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

Research Question:
Does the drug Darbe improve cognitive function in preterm infants?

Basic Study Information

Purpose:
Study Hypothesis: Preterm infants administered weekly Darbe during the neonatal period will have improved neurocognitive outcome at 22-26 months compared to placebo

Location: University of Rochester

Study Contact Information

Study Coordinator: Carl T D'Angio, MD
Phone: (505) 272-0180
Email: rohls@salud.unm.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search